Two co-founders of Fullerton Healthcare Corporation, Daniel Chan Pai Sheng and Michael Tan Kim Song, both 52-year-old medical doctors, have been fined a total of S$160,000 for orchestrating a scheme to falsify entertainment expense claims linked to more than S$211,000. The penalties were imposed on Friday, July 10, following guilty pleas entered two days earlier. Notably, neither man profited directly from the fraudulent claims; instead, the inflated expenses were channelled to benefit Collin Chiew, 58, a former chief executive of insurance broker Aon Singapore, whose own legal proceedings remain unresolved.
Chan bore the heavier financial penalty, facing a S$135,000 fine after admitting to five counts of falsification of accounts. The scope of his misconduct was substantial: the falsified claims totalled over S$336,000 when the legitimate underlying expenses amounted to merely S$125,000, creating an inflation of more than S$211,000. Tan's culpability, while narrower in scope, resulted in a S$25,000 fine following his guilty plea to a single count of account falsification. His particular offence involved a false entertainment claim of approximately S$82,000 against actual expenses exceeding S$42,000, yielding an inflated amount of nearly S$40,000 that formed part of the broader scheme uncovered by investigators.
The prosecution simultaneously moved to discharge all graft-related charges against both men, a decision the court approved. This procedural step—known as a discharge not amounting to an acquittal—is significant for Malaysian and regional observers of corporate governance and white-collar crime. Such discharges preserve the Crown's ability to reinitiate prosecutions should material new evidence emerge, effectively suspending rather than terminating certain charges. The prosecutorial discretion employed here suggests investigators and prosecutors concluded that the falsification convictions adequately addressed the core misconduct, even as broader corruption allegations remained legally unresolved.
The mechanics of the scheme reveal a carefully orchestrated operation spanning multiple jurisdictions. Between 2015 and the time of discovery, Chan regularly travelled to Hong Kong approximately twice monthly for business purposes connected to FHC's operations there. Before each journey, he would solicit inflated or entirely fabricated karaoke (KTV) receipts from David Sin, the company's third co-founder, who coordinated with Tei Chu Pink, 46, to generate the false documents. During his Hong Kong visits, Chan would attend KTV establishments alongside Sin and Tei, ostensibly to cultivate business relationships with potential investors. Upon his return to Singapore, Chan would distribute the inflated receipts to relevant personnel within FHC or its subsidiary Fullerton Health China, who then processed these claims through the company's formal financial systems.
What distinguishes this case from typical expense padding schemes is the sophisticated layering of false documentation with selective actual payments. On certain occasions, Chan would remit substantially reduced sums to the KTV venues using personal cash or credit cards, creating a documentary trail that appeared to support the inflated receipts. On other instances, no payment whatsoever was made at the establishments, yet falsified invoices were processed regardless. This approach minimised detection risks by generating at least some legitimate transaction records while simultaneously establishing the fictitious larger amounts needed to funnel money toward Chiew.
The connection to Chiew illuminates the underlying motivation. Court documents reveal that around 2012, while seeking new business opportunities, Tan and Chan were introduced to Chiew through professional channels. By 2015, Chiew approached Chan requesting financial assistance, citing pressing personal circumstances including educational expenses for his children and mortgage obligations. Chan consulted with Tan regarding the request, and the two agreed to devise a mechanism to channel funds covertly. Rather than providing direct loans or gifts that might raise corporate governance questions, they engineered the entertainment expense falsification scheme as a vehicle for transferring capital to Chiew while maintaining apparent legitimacy within the company's accounting frameworks.
The broader corporate structure involved multiple entities and jurisdictional layers, which likely facilitated the scheme's continuation. Tan held director positions at Fullerton Healthcare Group, the healthcare services subsidiary established in 2010, which operated a network of doctors and specialists while assisting clients with insurance claims processing. Chan served as president of Fullerton Health China, the offshore subsidiary. FHC itself functioned primarily as an investment holding company, a structural arrangement that can obscure the flow of funds between operating entities. Both men have since relinquished their respective positions, though the timing and circumstances of their departure remain undisclosed.
A third significant co-founder, David Sin, 47, had already been held accountable through the legal system. In August 2025, Sin pleaded guilty to six counts of falsification of accounts and received an identical S$160,000 fine, underscoring the systematic nature of the misconduct at the senior levels of the company. Sin's coordinating role in obtaining and distributing the false receipts proved critical to the scheme's execution, positioning him as a central operational figure despite the ultimate beneficiary being Chiew rather than the company's insiders.
For Malaysian and Southeast Asian business observers, this case underscores persistent vulnerabilities in corporate expense management and the mechanisms through which senior executives can exploit administrative systems. The involvement of offshore subsidiaries and international travel created multiple opportunities for documentation concealment, particularly where cross-border financial flows occur. The scheme operated over several years before detection, suggesting that standard internal audit procedures at FHC—or oversight by any parent company or board governance structure—proved inadequate to identify the pattern of falsification.
The case also illuminates the application of prosecutorial discretion in complex white-collar investigations. Choosing to discharge graft charges while pursuing falsification counts reflects a strategic assessment that the latter category of offence was both provable and sufficient to satisfy accountability objectives. This approach contrasts with jurisdictions that might pursue comprehensive charges across all applicable statutes. For regional business leaders and compliance officers, the message is clear: falsifying financial records for any purpose—whether for personal enrichment or to benefit third parties—triggers serious criminal liability regardless of the underlying motive.
The verdicts raise questions about internal controls and oversight mechanisms that failed to catch the scheme despite its multi-year operation and the involvement of multiple personnel in generating and processing false documentation. FHC's establishment as an investment holding company with subsidiaries operating in healthcare services and insurance claim processing suggests a complex organisational structure that may have hindered consolidated financial monitoring. The swift guilty pleas from both Chan and Tan, combined with Sin's earlier admission, indicate that the evidence presented by Singapore's Corrupt Practices Investigation Bureau proved overwhelming, leaving little room for contested proceedings.
For regulators and corporate governance advocates across Malaysia and the broader region, this matter reinforces the importance of robust financial controls, independent audit functions, and whistleblower mechanisms capable of detecting patterns of suspicious transactions across multiple subsidiary entities. The geographic dispersion of FHC's operations—with significant activities in Hong Kong and China—added complexity to oversight and created opportunities for concealment. As Southeast Asian companies increasingly establish regional operations and cross-border supply chains, the institutional capacity to detect fraudulent expense claims and financial misrepresentation demands continuous strengthening. The S$211,000 in falsified claims, while not extraordinary in absolute terms, represents the cumulative effect of systematic misconduct at the executive level, a pattern that sophisticated financial controls might have interrupted far earlier.
